ABBV-932 + Placebo
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Generalized Anxiety Disorder (GAD)
Conditions
Generalized Anxiety Disorder (GAD), Healthy Participants
Trial Timeline
Feb 15, 2023 → May 31, 2024
NCT ID
NCT05738850About ABBV-932 + Placebo
ABBV-932 + Placebo is a phase 1 stage product being developed by AbbVie for Generalized Anxiety Disorder (GAD). The current trial status is completed. This product is registered under clinical trial identifier NCT05738850. Target conditions include Generalized Anxiety Disorder (GAD), Healthy Participants.
What happened to similar drugs?
12 of 20 similar drugs in Generalized Anxiety Disorder (GAD) were approved
Approved (12) Terminated (3) Active (7)
✅Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatmentSumitomo PharmaApproved
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05738850 | Phase 1 | Completed |
Competing Products
20 competing products in Generalized Anxiety Disorder (GAD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine + placebo | Eli Lilly | Phase 2/3 | 38 |
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 32 |
| Perampanel | Eisai | Pre-clinical | 26 |
| Perampanel + Placebo comparator | Eisai | Phase 3 | 40 |
| zonisamide | Eisai | Pre-clinical | 26 |
| Fycompa | Eisai | Pre-clinical | 26 |
| Fycompa | Eisai | Pre-clinical | 26 |
| Perampanel | Eisai | Phase 3 | 40 |
| Perampanel | Eisai | Pre-clinical | 26 |
| Cenobamate | Ono Pharmaceutical | Phase 3 | 47 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 40 |
| Duloxetine + Placebo | Eli Lilly | Approved | 43 |
| Ixekizumab | Eli Lilly | Approved | 43 |
| eszopiclone + eszopiclone + Placebo | Sumitomo Pharma | Phase 2 | 35 |
| Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment | Sumitomo Pharma | Approved | 43 |
| ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT) | AbbVie | Phase 2 | 42 |
| Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day | AbbVie | Phase 2 | 27 |
| Escitalopram | AbbVie | Approved | 43 |
| Adalimumab | AbbVie | Phase 3 | 40 |
| Quetiapine fumarate + Paroxetine | AstraZeneca | Phase 3 | 40 |